Poor
Not Aligned
Patient Risk:
Low
Summary
Only one claim (“meningococcal conjugate vaccine”) is supported by the provided label section 11 (DESCRIPTION). The other packaging/manufacturer/country-of-origin claims are not supported by the provided label text, and no safety/usage label elements could be evaluated because they were not supplied.
Category Scores
Accurate Statements
Menactra is a meningococcal conjugate vaccine.
Supported by section 11 (DESCRIPTION), which describes Menactra containing N. meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens conjugated to diphtheria toxoid protein.
Unsupported Statements
Menactra is made by Sanofi Pasteur.
The provided label section 11 (DESCRIPTION) does not name the manufacturer (e.g., Sanofi Pasteur).
The country of origin of Menactra depends on the specific lot shipped to a country or market.
The provided label section 11 (DESCRIPTION) does not discuss country of origin, lot-specific origin, or shipment/market-dependent origin.
The country of origin for Menactra can vary by distribution region.
The provided label section 11 (DESCRIPTION) contains no information about variation of country of origin by distribution region.
The country of origin is typically printed on the package labeling and lot information (often on the carton and/or vial/inner label) for the particular batch.
The provided label section 11 (DESCRIPTION) does not address what is printed on packaging/labels or how country-of-origin information is presented.
Even when the manufacturer is the same, the final packaged Menactra product can come from different manufacturing and packaging sites depending on the production run and the destination market.
The provided label section 11 (DESCRIPTION) does not describe multiple manufacturing/packaging sites, production-run variability, or destination-market differences.
Contradictions
Important Omissions
Safety/label compliance could not be assessed because label sections relevant to contraindications, boxed warnings, warnings/precautions, dosing/administration, and specific populations were not provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only supported claim is descriptive (vaccine type). The unsupported claims relate to manufacturing/origin/labeling logistics; no dosing, contraindications, boxed warnings, or clinical safety guidance were claimed in the provided text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Most claims (manufacturer and country-of-origin/labeling logistics) are not supported by the provided FDA label text; only the vaccine type claim is supported by section 11.
Suggested Improvement
Limit assertions to label-supported content from the provided section 11, or provide the relevant FDA label sections that explicitly address manufacturer and country-of-origin/lot/packaging labeling details before making those claims.